Some experts have raised concerned about 23andMe's new direct-to-consumer pharmacogenetic tests, Time reports.

The US Food and Drug Administration earlier this week gave 23andMe authorization to sell tests for 33 variants linked to the ability to break down certain drugs, as GenomeWeb has reported.